Carbamazepine (Epilepsy)

Neonatal medical care

id	Study   Auto Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020Aydin (Carbamazepine) (Controls unexposed, sick), 2020Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013Artama (Carbamazepine) (Controls unexposed, disease free), 2013Artama (Carbamazepine) (Controls unexposed, sick), 2013Viinikainen (Carbamazepine) (Controls unexposed, disease free) a, 2006D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991D'Souza (Carbamazepine) (Controls unexposed, sick), 1991	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S15365 R63211	Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023	Neonatal special care admission	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.54 [0.15;1.96] C excluded (control group)	3/27   20/106	23	27		ref
S15366 R63224	Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023	Neonatal special care admission	during pregnancy (anytime or not specified)	prospective cohort	unexposed, sick	Adjustment: No	1.54 [0.36;6.64] C	3/27   6/80	9	27		ref
S8082 R24682	Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.38 [0.04;3.52] C excluded (control group)	2/15   2/7	4	15		ref
S8074 R24630	Aydin (Carbamazepine) (Controls unexposed, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	1.54 [0.19;12.32] C	2/15   2/22	4	15		ref
S5925 R15065	Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	0.59 [0.36;0.96] C excluded (control group)	89/904   24/154	113	904		ref
S5909 R14880	Artama (Carbamazepine) (Controls unexposed, disease free), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, disease free excluded	Adjustment: Yes	1.44 [1.16;1.80] excluded (control group)	89/904   49,612/689,482	49,701	904		ref
S5917 R14976	Artama (Carbamazepine) (Controls unexposed, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, sick	Adjustment: Yes	1.17 [0.88;1.55]	89/904   152/1,708	241	904		ref
S6167 R16224	Viinikainen (Carbamazepine) (Controls unexposed, disease free) a, 2006	Admission to a neonatal unit	throughout pregnancy	prospective cohort	unexposed, disease free	Adjustment: No	1.15 [0.50;2.65] C	6/72   1,822/24,778	1,828	72		ref
S6685 R18603	D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991	Idiopathic respiratory distress	throughout pregnancy	prospective cohort	unexposed, disease free excluded	Adjustment: No Matched	24.60 [0.40;1512.72] C excluded (control group)	0/3   0/62	0	3		ref
S6689 R18720	D'Souza (Carbamazepine) (Controls unexposed, sick), 1991	Idiopathic respiratory distress	throughout pregnancy	prospective cohort	unexposed, sick	Adjustment: No	3.00 [0.05;194.76] C	0/3   0/8	0	3		ref
					Total	5 studies	1.19 [0.91;1.54]		2,082	1,021
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 6685, 5925, 5909, 8082, 15365